Millendo Therapeutics, Inc. (MLND)
Millendo Therapeutics, Inc. operates in the Biotechnology industry of the Healthcare sector, headquartered in Ann Arbor, MI, US. The stock last traded at $1.06, down 5.36% on the session, giving a market capitalisation of $11.1M. On trailing twelve-month figures it carries a trailing P/E of -0.19, a net margin of 0.0%. Its beta of 0.48 implies it has historically moved less than the broad market.
Millendo Therapeutics, Inc. is an advanced biopharmaceutical firm dedicated to developing innovative therapies for rare hormonal disorders, primarily within the United States. The company's key therapeutic candidates include livoletide, an investigational drug aimed at Prader-Willi syndrome; nevanimibe, an experimental compound designed for patients with classic congenital adrenal hyperplasia; and MLE-301, a neurokinin 3-receptor antagonist intended to alleviate vasomotor symptoms (such as hot flashes) in women experiencing menopause. This enterprise maintains its primary operational base in Ann Arbor, Michigan.
Millendo Therapeutics, Inc. is most often compared with the following Healthcare names: